Waite Robert A, Malinowski Jennifer M
Department of Pharmacy Practice, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, Pennsylvania 18766, USA.
Pharmacotherapy. 2002 Mar;22(3):391-4. doi: 10.1592/phco.22.5.391.33188.
Pericarditis should be considered in any patient complaining of chest pain and/or dyspnea who is taking a product that contains mesalamine or sulfasalazine. A 41-year-old woman was taking mesalamine 800 mg 3 times/day for 3 weeks before hospital admission. She complained of sharp, pleuritic chest pain that radiated down both arms and increased in intensity when lying down. She was diagnosed with pericarditis based on clinical presentation and electrocardiogram findings. Differential diagnoses for myocardial infarction, systemic lupus erythematosus, and viral or bacterial causes were ruled out based on subjective and objective data. Mesalamine-induced pericarditis was considered on hospital day 2, and the drug was discontinued at discharge on day 3. Clinicians should be aware of this potential drug-related complication, as the relationship between mesalamine or sulfasalazine and pericarditis has been reported rarely in the literature.
对于任何正在服用含有美沙拉嗪或柳氮磺胺吡啶产品且主诉胸痛和/或呼吸困难的患者,都应考虑心包炎的可能。一名41岁女性在入院前3周每天服用3次800毫克美沙拉嗪,共3周。她主诉尖锐的胸膜炎性胸痛,疼痛放射至双臂,躺下时疼痛加剧。根据临床表现和心电图结果,她被诊断为心包炎。基于主观和客观数据,排除了心肌梗死、系统性红斑狼疮以及病毒或细菌感染等鉴别诊断。在住院第2天考虑为美沙拉嗪诱发的心包炎,第3天出院时停用了该药物。临床医生应意识到这种潜在的药物相关并发症,因为美沙拉嗪或柳氮磺胺吡啶与心包炎之间的关系在文献中鲜有报道。